EPIRUBICIN HYDROCHLORIDE INJECTION SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

EPIRUBICIN HYDROCHLORIDE

可用日期:

PFIZER CANADA ULC

ATC代码:

L01DB03

INN（国际名称）:

EPIRUBICIN

剂量:

2MG

药物剂型:

SOLUTION

组成:

EPIRUBICIN HYDROCHLORIDE 2MG

给药途径:

INTRAVENOUS

每包单位数:

100ML

处方类型:

Prescription

治疗领域:

ANTINEOPLASTIC AGENTS

產品總結:

Active ingredient group (AIG) number: 0116901002; AHFS:

授权状态:

MARKETED

授权日期:

2008-11-24

产品特点

PRODUCT MONOGRAPH
PR
EPIRUBICIN HYDROCHLORIDE INJECTION
2 MG/ML
PROFESSED STANDARD
ANTINEOPLASTIC AGENT
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Control No.: 209065
Date of Revision:
October 6, 2017
_Product Monograph - _
_Pr_
_ Epirubicin Hydrochloride Injection _
_Page 2 of 37_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................19
SPECIAL HANDLING INSTRUCTIONS
.......................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
...............................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
CLINICAL TRIALS
........................................................................